12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Forxiga dapagliflozin regulatory update

Bristol-Myers and partner AstraZeneca said the European Commission approved Forxiga dapagliflozin to treat Type II diabetes. The partners said the approval is the first for a sodium-glucose cotransporter 2 (SGLT2) inhibitor for...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >